Big Tobacco Eyes European Cannabis Growth Through Strategic Acquisitions

In the past 48 hours, the cannabis industry shows consolidation driven by Big Tobacco, with Canadian firm Organigram announcing its acquisition of Berlins Sanity Group for up to 227 million euros, backed by a 65 million Canadian dollar injection from shareholder British American Tobacco, which holds 41 percent of Organigram.[2] This marks the largest deal in Germanys medical cannabis market, where Sanity surged from fifth to second-largest supplier, with revenue jumping from 9 million euros in 2023 to 60 million euros in 2025.[2] No major market movements, price changes, or supply chain disruptions appear in recent data, though US stocks like Tilray Brands, Canopy Growth, Organigram, Cronos Group, Aurora Cannabis, Silver Spike, and SNDL drew high trading volume on March 5.[7] Canopy Growth reported double-digit Canadian cannabis revenue growth in its Q3 fiscal 2026 results on February 6, narrowing net losses with 371 million dollars in cash.[6] Regulatory notes include Germanys pending bill restricting telemedical cannabis, adding caution to the Sanity deal,[2] and the US 2026 Farm Bill advancing without changes to its intoxicating hemp ban.[8] NewLake Capital Partners declared a Q1 2026 dividend of 0.43 dollars per share amid steady operations.[11] Compared to prior weeks, Big Tobaccos moves echo patterns like Philip Morriss 2023 Syqe Medical deal and Altrias Cronos stake, with over 6 billion dollars invested industry-wide.[2] Leaders like BAT respond to shrinking tobacco sales by pivoting to Europes growth markets amid North American maturity.[2] No shifts in consumer behavior or new launches surfaced in the latest 48 hours, signaling a focus on strategic M&A over volatility. (248 words) For great deals today, check out https://amzn.to/44ci4hQ This content was created in partnership and with the help of Artificial Intelligence AI.